Back to GetFilings.com



Table of Contents

________________________________________________________________________________

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q

  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  For the quarterly period ended March 31, 2003

or

  [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  For the transition period from            to           

Commission file number 0-24975

WEBMD CORPORATION

(Exact name of registrant as specified in its charter)
     
Delaware
  94-3236644
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)

669 River Drive, Center 2

Elmwood Park, New Jersey 07407-1361
(Address of principal executive offices)

(201) 703-3400

(Registrant’s telephone number, including area code)


     Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x     No o

      Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes x     No o

As of May 8, 2003, there were 303,120,851 shares of the

registrant’s Common Stock outstanding.




TABLE OF CONTENTS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
PART I
ITEM 1. Financial Statements
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED STATEMENTS OF OPERATIONS
CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
ITEM 4. Controls and Procedures
PART II OTHER INFORMATION
ITEM 2. Changes in Securities and Use of Proceeds
ITEM 6. Exhibits and Reports on Form 8-K
SIGNATURES
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
EXHIBIT INDEX
EX-99.1 SECTION 906 CERTIFICATION OF THE CEO
EX-99.2 SECTION 906 CERTIFICATION OF THE CFO


Table of Contents

WEBMD CORPORATION

QUARTERLY REPORT ON FORM 10-Q

For the period ended March 31, 2003

TABLE OF CONTENTS

             
Page
Number

Cautionary Statement Regarding Forward-Looking Statements     3  
Part I
 
Financial Information
       
Item 1.
 
Financial Statements:
       
   
Consolidated Balance Sheets as of March 31, 2003 (unaudited) and December 31, 2002
    4  
   
Unaudited Consolidated Statements of Operations for the three months ended March 31, 2003 and 2002
    5  
   
Unaudited Consolidated Statements of Cash Flows for the three months ended March 31, 2003 and 2002
    6  
   
Notes to Consolidated Financial Statements
    7  
Item 2.
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
    17  
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk
    39  
Item 4.
 
Controls and Procedures
    39  
Part II
 
Other Information
       
Item 2.
 
Changes in Securities and Use of Proceeds
    40  
Item 6.
 
Exhibits and Reports on Form 8-K
    40  
Signatures     41  
Exhibit Index     E-1  

WebMD®, WebMD Health®, The Medical Manager®, ULTIATM, IntergyTM, Envoy®, ExpressBill®, Medscape®, WellMed® and POREX® are trademarks of WebMD Corporation or its subsidiaries.

2


Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

      This Quarterly Report on Form 10-Q contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, forward-looking statements. These forward-looking statements are not based on historical facts, but rather reflect management’s current expectations concerning future results and events. These forward-looking statements generally can be identified by use of expressions such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “likely,” “will” or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. In addition to the risk factors described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Factors That May Affect Our Future Financial Condition or Results of Operations” beginning on page 26, the following important risks and uncertainties could affect future results, causing these results to differ materially from those expressed in our forward-looking statements:

  •  the failure to achieve sufficient levels of customer utilization and market acceptance of new services or newly integrated services,
 
  •  the inability to successfully deploy new applications or newly integrated applications,
 
  •  difficulties in forming and maintaining mutually beneficial relationships with customers and strategic partners,
 
  •  the inability to attract and retain qualified personnel, and
 
  •  general economic, business or regulatory conditions affecting the healthcare, information technology, Internet and plastic industries being less favorable than expected.

      These factors and the risk factors described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Factors That May Affect Our Future Financial Condition or Results of Operations” beginning on page 26 are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could have material adverse effects on our future results. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this Quarterly Report. We expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

3


Table of Contents

PART I

FINANCIAL INFORMATION

 
ITEM 1.     Financial Statements

WEBMD CORPORATION

 
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
                     
March 31, December 31,
2003 2002


(Unaudited)
ASSETS
               
Current assets:
               
 
Cash and cash equivalents
  $ 252,652     $ 179,541  
 
Short-term investments
    214,276       10,888  
 
Accounts receivable, net
    176,571       170,467  
 
Inventory
    18,489       18,804  
 
Current portion of prepaid content and distribution services
    25,660       25,406  
 
Other current assets
    18,447       26,197  
     
     
 
   
Total current assets
    706,095       431,303  
 
Marketable debt securities
    218,602       449,289  
Marketable equity securities
    7,407       7,427  
Property and equipment, net
    91,714       94,737  
Prepaid content and distribution services
    42,324       48,532  
Goodwill
    629,217       629,055  
Intangible assets, net
    58,989       79,536  
Other assets
    26,240       26,369  
     
     
 
    $ 1,780,588     $ 1,766,248  
     
     
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
 
Accounts payable
  $ 11,711     $ 11,494  
 
Accrued expenses
    207,992       212,600  
 
Deferred revenue
    85,365       81,179  
 
Current portion of long-term debt
    6,546       6,546  
     
     
 
   
Total current liabilities
    311,614       311,819  
 
Convertible subordinated notes
    300,000       300,000  
Other long-term liabilities
    605       628  
 
Commitments and contingencies
               
 
Stockholders’ equity:
               
 
Common stock, $0.0001 par value; 600,000,000 shares authorized; 378,482,167 shares issued at March 31, 2003; 374,661,064 shares issued at December 31, 2002.
    38       37  
 
Additional paid-in capital
    11,699,274       11,682,443  
 
Deferred stock compensation
    (13,836 )     (17,805 )
 
Treasury stock, at cost; 74,265,669 shares at March 31, 2003; 74,254,669 shares at December 31, 2002.
    (327,635 )     (327,542 )
 
Accumulated deficit
    (10,202,406 )     (10,195,048 )
 
Accumulated other comprehensive income
    12,934       11,716  
     
     
 
   
Total stockholders’ equity
    1,168,369       1,153,801  
     
     
 
    $ 1,780,588     $ 1,766,248  
     
     
 

See accompanying notes.

4


Table of Contents

WEBMD CORPORATION

 
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
                   
Three Months Ended
March 31,

2003 2002


Revenue
  $ 234,743     $ 225,873  
Costs and expenses:
               
 
Cost of operations
    134,380       138,531  
 
Development and engineering
    11,012       10,868  
 
Sales, marketing, general and administrative
    70,070       79,366  
 
Depreciation and amortization
    27,976       32,759  
 
Restructuring and integration benefit
          3,750  
 
Gain on investments
    183        
 
Interest income
    5,055       3,140  
 
Interest expense
    2,921       141  
     
     
 
Loss before income tax provision
    (6,378 )     (28,902 )
 
Income tax provision
    980       700  
     
     
 
Net loss
  $ (7,358 )   $ (29,602 )
     
     
 
Basic and diluted net loss per common share
  $ (0.02 )   $ (0.09 )
     
     
 
Weighted-average shares outstanding used in computing basic and diluted net loss per common share
    302,892       311,668  
     
     
 

See accompanying notes.

5


Table of Contents

WEBMD CORPORATION

 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
                         
Three Months Ended
March 31,

2003 2002


Cash flows from operating activities:
               
 
Net loss
  $ (7,358 )   $ (29,602 )
 
Adjustments to reconcile net loss to net cash provided by operating activities:
               
   
Depreciation and amortization
    27,976       32,759  
   
Amortization of debt issuance costs
    375        
   
Non-cash content and distribution services
    6,146       7,260  
   
Non-cash stock-based compensation
    3,757       7,576  
   
Gain on investments
    (183 )      
   
Changes in operating assets and liabilities:
               
     
Accounts receivable
    (6,074 )     (1,692 )
     
Inventory
    315       (1,894 )
     
Prepaid content and distribution services
    (191 )     (1,649 )
     
Accounts payable
    190       (3,389 )
     
Accrued expenses
    (4,610 )     10,049  
     
Deferred revenue
    4,112       8,393  
     
Other, net
    9,495       807  
     
     
 
       
Net cash provided by operating activities
    33,950       28,618  
 
Cash flows from investing activities:
               
 
Proceeds from maturities of available-for-sale securities
    801       79,248  
 
Proceeds from maturities and redemptions of held-to-maturity securities
    101,919       1,055  
 
Purchases of available-for-sale securities
    (1,164 )      
 
Purchases of held-to-maturity securities
    (75,119 )     (156,714 )
 
Purchases of property and equipment
    (4,022 )     (5,753 )
 
Cash paid in business combinations, net of cash acquired
    (344 )     (1,142 )
     
     
 
       
Net cash provided by (used in) investing activities
    22,071       (83,306 )
 
Cash flows from financing activities:
               
 
Proceeds from issuance of common stock
    17,025       5,351  
 
Payments of notes payable and other
    (19 )     (645 )
 
Redemption of Series B Preferred Stock
          (10,000 )
 
Purchases of treasury stock
    (93 )      
     
     
 
       
Net cash provided by (used in) financing activities
    16,913       (5,294 )
Effect of exchange rates on cash
    177       (121 )
     
     
 
Net increase (decrease) in cash and cash equivalents
    73,111       (60,103 )
Cash and cash equivalents at beginning of period
    179,541       286,273  
     
     
 
Cash and cash equivalents at end of period
  $ 252,652     $ 226,170  
     
     
 

See accompanying notes.

6


Table of Contents

WEBMD CORPORATION

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data, unaudited)
 
1.  Summary of Significant Accounting Policies

Basis of Presentation

      The unaudited consolidated financial statements of WebMD Corporation (the “Company”) have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 2003 are not necessarily indicative of the results to be expected for any subsequent period or for the entire year ending December 31, 2003. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted under the Securities and Exchange Commission’s rules and regulations.

      Porex Corporation and the Company’s other Plastic Technologies subsidiaries (collectively referred to as “Porex”) had previously been reported as an asset held for sale during the period from September 12, 2000 to September 12, 2001, and as a discontinued operation from September 13, 2001 to September 30, 2002. During February 2003, the Company terminated its divestiture plan for Porex. Accordingly, the assets and operations of Porex have been reclassified within continuing operations since September 12, 2000, its date of acquisition. The operations of Porex have been included in a separate operating segment, “Plastic Technologies.”

      The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2002, which were included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Accounting Estimates

      The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from these estimates. Significant estimates and assumptions by management affect: the Company’s allowance for doubtful accounts, the carrying value of inventory, the carrying value of prepaid content and distribution services, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill), the carrying value, capitalization and amortization of software development costs, the carrying value of short-term and long-term investments, the provision for taxes and related deferred tax accounts, certain accrued expenses, revenue recognition, restructuring costs and the value attributed to warrants issued for services.

Inventory

      Inventory is stated at the lower of cost or market value using the first-in, first-out basis. Cost includes raw materials, direct labor, and manufacturing overhead. Market value is based on current replacement

7


Table of Contents

WEBMD CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

cost for raw materials and supplies and on net realizable value for work-in-process and finished goods. Inventory consisted of the following as of March 31, 2003 and December 31, 2002:

                 
March 31, December 31,
2003 2002


Raw materials and supplies
  $ 5,526     $ 5,869  
Work-in-process
    1,594       1,481  
Finished goods and other
    11,369       11,454  
     
     
 
    $ 18,489     $ 18,804  
     
     
 

Accounting for Stock-Based Compensation

      The Company accounts for its stock-based employee compensation plans using the intrinsic value method under the recognition and measurement principles of APB Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB No. 25”), and related interpretations. No stock-based employee compensation cost is reflected in net loss with respect to options granted with an exercise price equal to the market value of the underlying common stock on the date of grant. Stock-based awards to non-employees are accounted for based on provisions of SFAS No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”) and EITF 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.” In accordance with SFAS No. 148 “Accounting for Stock-Based Compensation — Transition and Disclosure — An Amendment of FASB Statement No. 123,” the following table illustrates the effect on net loss and net loss per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation:

                   
Three Months Ended
March 31,

2003 2002


Net loss as reported
  $ (7,358 )   $ (29,602 )
Deduct: Stock-based employee compensation expense included in reported net loss
    3,757       7,576  
Add: Total stock-based employee compensation expense determined under fair value based method for all awards
    (17,958 )     (32,782 )
     
     
 
Pro forma net loss
  $ (21,559 )   $ (54,808 )
     
     
 
Net loss per common share:
               
 
Basic and diluted — as reported
  $ (0.02 )   $ (0.09 )
     
     
 
 
Basic and diluted — pro forma
  $ (0.07 )   $ (0.18 )
     
     
 

      The pro forma results above are not intended to be indicative of or a projection of future results. Pro forma information regarding net loss has been determined as if employee stock options granted subsequent to December 31, 1994 were accounted for under the fair value method of SFAS No. 123. The fair value for 2003 options was estimated at the date of grant using the Black-Scholes option pricing model employing weighted average assumptions consistent with the 2002 assumptions, which were included in Note 15 to the Consolidated Financial Statements contained in the Company’s 2002 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

      The Company has elected to follow APB No. 25 and related interpretations in accounting for employee stock options because the alternative fair value accounting method provided for under SFAS No. 123 requires the use of option valuation models that were not developed for use in valuing employee stock options. The Black-Scholes option valuation model was developed for use in estimating the fair value

8


Table of Contents

WEBMD CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimates, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s employee stock options.

Reclassifications

      Certain reclassifications have been made to the prior period financial statements to conform with the current period presentation.

 
2.  Business Combinations

2003 Acquisitions

      During the three months ended March 31, 2003, the Company acquired one physician services company for a cost of $350, which was paid in cash. This acquisition was accounted for using the purchase method of accounting with the purchase price being allocated to assets acquired and liabilities assumed based on their fair values. In connection with the preliminary allocation of the purchase price, goodwill of $197 and intangible assets subject to amortization of $192 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible assets are comprised of $96 related to a non-compete agreement with an estimated useful life of three years and $96 related to customer relationships with an estimated useful life of nine years. The results of operations of this company have been included in the financial statements of the Company from the acquisition closing date and are included in the Physician Services segment.

2002 Acquisitions

      On October 31, 2002, the Company acquired WellMed, Inc. (“WellMed”), which develops and markets healthcare information technology applications, including online healthcare decision support and health management tools for use by consumers. The total purchase consideration for WellMed was approximately $19,031, comprised of $18,781 in cash and estimated acquisition costs of $250. The acquisition was accounted for using the purchase method of accounting and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and the liabilities assumed on the basis of their respective fair values. In connection with the preliminary allocation of the purchase price, goodwill of $17,973 and an intangible asset subject to amortization of $2,700 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible asset represents the fair value of acquired unpatented technology and has a useful life of three years. The results of operations of WellMed have been included in the financial statements of the Company from October 31, 2002, the closing date of the acquisition. WellMed’s results of operations are included in the Portal Services segment.

      In 2002, the Company acquired 21 physician services companies for a total cost of $14,400, which was paid in cash. These acquisitions were accounted for using the purchase method of accounting with the purchase price being allocated to assets acquired and liabilities assumed based on their fair values. In connection with the preliminary allocation of the purchase price, goodwill of $11,784 and intangible assets subject to amortization of $4,049 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible assets are comprised of $1,281 related to non-compete agreements with estimated useful lives of one to five years and $2,768 related to customer relationships with estimated useful lives of nine years. The results of operations of these companies have

9


Table of Contents

WEBMD CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

been included in the financial statements of the Company from the respective acquisition closing dates and are included in the Physician Services segment.

      The pro forma impact of the 2003 Acquisitions and the 2002 Acquisitions was not significant in any of the periods presented.

3. Restructuring and Integration

      After the mergers with Medical Manager Corporation, CareInsite, Inc. and OnHealth Network Company in September 2000, the Company’s Board of Directors approved a restructuring and integration plan, with the objective of eliminating duplication and redundancies that resulted from the acquisitions made by the Company since November 1999 and consolidating the Company’s operational infrastructure into a common platform to more efficiently serve its customers.

      Additionally, as part of the Company’s restructuring and integration efforts, the Company also undertook a review of its existing strategic relationships in light of several criteria, including strategic relevance to both the Company and the Company’s partners, potential conflicts with other agreements as a result of the numerous acquisitions made by the Company, profitability and impact on future revenue streams. These reviews resulted in significant revisions to some of the Company’s strategic relationships. The Company’s restructuring and integration efforts continued in 2001, and a plan to include the impact of eliminating functions resulting from the Company’s acquisition of Medscape in December 2001 was initiated. Additionally, the Plastic Technologies segment consolidated a manufacturing facility in 2002 as part of a separate restructuring plan.

      The Company has substantially completed its restructuring and integration efforts. The balance of the restructuring and integration accrual as of March 31, 2003 is primarily related to remaining lease payments of previously vacated facilities. The following table presents cash activity in the restructuring and integration related accrual:

                         
Severance Facilities Total



Balance at December 31, 2002
  $ 244     $ 33,613     $ 33,857  
Accruals
                 
Cash payments
    (50 )     (1,915 )     (1,965 )